Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MotherNature.com

This article was originally published in The Tan Sheet

Executive Summary

Supplements e-tailer cost-savings moves have included cutting more than half of its workforce, bringing its headcount to "approximately 100" from a high of 220, firm announces Oct. 24. Although third quarter sales nearly doubled to $3 mil. compared to the year-ago period, consecutive quarter results were down 11.8%. MotherNature reports a net loss of $6.7 mil. for the three months compared to $18.8 mil. in the 1999 period. The online marketer recently created a division devoted to developing e-commerce platforms for natural product sellers. The program helps small retailers and regional chains set up Web sites and provides inventory and fulfillment services (1"The Tan Sheet" Sept. 25, p. 14)

You may also be interested in...



MotherNature.com Board Approves Liquidation Plan

MotherNature.com's board of directors has decided to cease operation "as an independent enterprise indefinitely" due to limited growth potential and availability of financing.

MotherNature.com Board Approves Liquidation Plan

MotherNature.com's board of directors has decided to cease operation "as an independent enterprise indefinitely" due to limited growth potential and availability of financing.

MotherNature.com Board Approves Liquidation Plan

MotherNature.com's board of directors has decided to cease operation "as an independent enterprise indefinitely" due to limited growth potential and availability of financing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel